Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells
- PMID: 16648140
- DOI: 10.1074/jbc.M511525200
Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells
Abstract
The major histocompatibility complex class I molecules consist of three subunits, the 45-kDa heavy chain, the 12-kDa beta(2)-microglobulin (beta(2)m), and an approximately 8-9-residue antigenic peptide. Without beta(2)m, the major histocompatibility complex class I molecules cannot assemble, thereby abolishing their transport to the cell membrane and the subsequent recognition by antigen-specific T cells. Here we report a case of defective antigen presentation caused by the expression of a beta(2)m with a Cys-to-Trp substitution at position 25 (beta(2)m(C25W)). This substitution causes misfolding and degradation of beta(2)m(C25W) but does not result in complete lack of human leukocyte antigen (HLA) class I molecule expression on the surface of melanoma VMM5B cells. Despite HLA class I expression, VMM5B cells are not recognized by HLA class I-restricted, melanoma antigen-specific cytotoxic T lymphocytes even following loading with exogenous peptides or transduction with melanoma antigen-expressing viruses. Lysis of VMM5B cells is restored only following reconstitution with exogenous or endogenous wild-type beta(2)m protein. Together, our results indicate impairment of antigenic peptide presentation because of a dysfunctional beta(2)m and provide a mechanism for the lack of close association between HLA class I expression and susceptibility of tumor cells to cytotoxic T lymphocytes-mediated lysis in malignant diseases.
Similar articles
-
Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.J Immunol. 2005 Feb 1;174(3):1462-71. doi: 10.4049/jimmunol.174.3.1462. J Immunol. 2005. PMID: 15661905 Free PMC article.
-
Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression.Tissue Antigens. 1996 May;47(5):382-90. doi: 10.1111/j.1399-0039.1996.tb02573.x. Tissue Antigens. 1996. PMID: 8795138
-
Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B.Cancer Sci. 2007 Nov;98(11):1795-802. doi: 10.1111/j.1349-7006.2007.00586.x. Epub 2007 Aug 28. Cancer Sci. 2007. PMID: 17725806 Free PMC article.
-
Beta2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance.Melanoma Res. 1997 Aug;7 Suppl 2:S67-74. Melanoma Res. 1997. PMID: 9578419 Review.
-
The role of surface HLA-A,B,C molecules in tumour immunity.Cancer Surv. 1992;13:101-27. Cancer Surv. 1992. PMID: 1423320 Review.
Cited by
-
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes.Cancer Immunol Immunother. 2012 Sep;61(9):1359-71. doi: 10.1007/s00262-012-1321-6. Epub 2012 Jul 26. Cancer Immunol Immunother. 2012. PMID: 22833104 Free PMC article. Review.
-
Oncogenic growth factor signaling mediating tumor escape from cellular immunity.Curr Opin Immunol. 2017 Apr;45:52-59. doi: 10.1016/j.coi.2017.01.004. Epub 2017 Feb 14. Curr Opin Immunol. 2017. PMID: 28208102 Free PMC article. Review.
-
A diversity of novel type-2 innate lymphoid cell subpopulations revealed during tumour expansion.Commun Biol. 2024 Jan 3;7(1):12. doi: 10.1038/s42003-023-05536-0. Commun Biol. 2024. PMID: 38172434 Free PMC article.
-
Specific cannabinoids revive adaptive immunity by reversing immune evasion mechanisms in metastatic tumours.Front Immunol. 2023 Feb 22;13:982082. doi: 10.3389/fimmu.2022.982082. eCollection 2022. Front Immunol. 2023. PMID: 36923728 Free PMC article.
-
Immunotherapy for melanoma: current status and perspectives.J Immunother. 2010 Jul-Aug;33(6):570-90. doi: 10.1097/CJI.0b013e3181e032e8. J Immunother. 2010. PMID: 20551839 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials